Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients Journal Article
| Authors: | Lee, Y. J.; Neofytos, D.; Kim, S. J.; Cheteyan, L.; Huang, Y. T.; Papadopoulos, E. B.; Jakubowski, A. A.; Papanicolaou, G. A. |
| Article Title: | Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients |
| Abstract: | Allogeneic hematopoietic cell transplant (HCT) recipients are at risk for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Routine prophylaxis with acyclovir is recommended during periods of immunosuppression. Brincidofovir (BCV, CMX001), a lipid conjugate of cidofovir, has shown in vitro activity against HSV/VZV, but has not been formally studied for HSV/VZV prophylaxis. We report our clinical experience of BCV for HSV/VZV prophylaxis in HCT recipients. This was a retrospective review of 30 hematopoietic cell transplant (HCT) recipients between 8/2010 and 8/2015 who received BCV doses not exceeding 200 mg/week for adults/adolescents and 4 mg/kg/week for pediatric (<12 years) patients, for ≥14 days BCV without concomitant acyclovir under clinical trials or single patient use. HSV/VZV cases during BCV treatment were confirmed by viral culture or PCR and clinical symptoms. Of 30 patients who met the inclusion criteria, 27 (90%) patients were adults and 22 (73%) patients received T-cell depleted HCT. The most common indications for BCV were cytomegalovirus in 12 patients (40%) and adenovirus in 11 patients (37%). One patient was treated for acyclovir-resistant HSV and one for disseminated VZV. There were two breakthrough cases of HSV infection during 2170 patient-days. There were no cases of breakthrough VZV infection. The overall rate of breakthrough HSV infection was 1.0 per 1000 patient-days, without any breakthrough VZV infections. Our study provides the only available—albeit limited—evidence on the potential efficacy of BCV for HSV/VZV prophylaxis in HCT patients. Additional studies are needed to further assess the efficacy and safety of BCV in the setting. © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
| Keywords: | hematopoietic cell transplant; brincidofovir; herpes simplex virus (hsv); varicella-zoster virus (vzv) |
| Journal Title: | Transplant Infectious Disease |
| Volume: | 20 |
| Issue: | 6 |
| ISSN: | 1398-2273 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2018-12-01 |
| Start Page: | e12977 |
| Language: | English |
| DOI: | 10.1111/tid.12977 |
| PROVIDER: | scopus |
| PMCID: | PMC6310478 |
| PUBMED: | 30120866 |
| DOI/URL: | |
| Notes: | Transplant Infect. Dis. -- Export Date: 2 January 2019 -- Article -- CODEN: TIDSF -- Source: Scopus C7 - e12977 |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
50Lee -
238Papanicolaou -
415Papadopoulos -
455Jakubowski -
28Huang -
7Neofytos -
13
Kim -
2
Cheteyan
Related MSK Work